References

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database

10.1016/s1470-2045(16)30500-9 · 2016 · External reference

Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review

10.1016/j.critrevonc.2016.01.017 · 2016 · External reference

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer

10.1200/jco.2003.04.187 · 2003 · External reference

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

10.1016/s1470-2045(20)30599-4 · 2021 · External reference

Quality of life and minimal clinically important difference in colorectal cancer patients undergoing hyperthermic intraperitoneal chemotherapy: a large prospective cohort study

10.1245/s10434-025-18147-2 · 2025 · External reference

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis

10.1111/codi.15003 · 2020 · External reference

Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

10.1002/bjs5.50179 · 2019 · External reference

Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis

10.1097/sla.0000000000001593 · 2016 · External reference

Colic and rectal tumors with peritoneal metastases treated with cytoreductive surgery and HIPEC: one homogeneous condition or two different diseases? A systematic review and meta-analysis

10.1016/j.ejso.2019.06.020 · 2019 · External reference

Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: a systematic review and meta-analysis

10.1016/j.ejso.2024.108474 · 2024 · External reference

The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases

10.1016/j.ejso.2022.06.014 · 2022 · External reference

Microsatellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

10.1245/s10434-021-11045-3 · 2022 · External reference

Pelvic peritonectomy poorly affects outcomes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal metastases

10.1007/s11605-022-05501-y · 2023 · External reference

The association of tumor laterality and survival after cytoreduction for colorectal carcinomatosis

10.1016/j.jss.2019.10.001 · 2020 · External reference

Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis

10.1097/sla.0b013e3182263933 · 2011 · External reference

Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: italian multicenter study S.I.T.I.L.O

10.1016/j.ejso.2010.10.014 · 2011 · External reference

Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients

10.1097/dcr.0000000000000149 · 2014 · External reference

Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin

10.1016/j.ejso.2014.06.006 · 2014 · External reference

Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology

10.1002/jso.23784 · 2015 · External reference

Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands

10.1016/j.ejso.2015.01.018 · 2015 · External reference

Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer

10.1245/s10434-015-4627-8 · 2016 · External reference

What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures

10.1002/jso.24248 · 2016 · External reference

Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases

10.1016/j.ejso.2016.03.014 · 2016 · External reference

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort

10.1002/jso.24290 · 2016 · External reference

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St george hospital, Australia

10.1111/ans.13152 · 2016 · External reference

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in adolescent and young adults with peritoneal metastases

10.1245/s10434-016-5689-y · 2017 · External reference

Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: what survival can we expect?

10.1016/j.ejca.2018.04.015 · 2018 · External reference

Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a comparative study

10.1016/j.ejso.2018.08.012 · 2018 · External reference

Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study

10.1245/s10434-019-07294-y · 2019 · External reference

Does primary tumor side matter in patients with metastatic Colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

10.1245/s10434-019-07255-5 · 2019 · External reference

The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

10.1186/s12957-020-1784-4 · 2020 · External reference

Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer

10.4251/wjgo.v12.i8.903 · 2020 · External reference

Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study

10.1016/j.ejso.2020.04.018 · 2020 · External reference

Patients with colorectal peritoneal metastases and high peritoneal cancer index May benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

10.1016/j.ejso.2020.07.039 · 2020 · External reference

Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis

2021 · External reference

Site of recurrence and survival after surgery for colorectal peritoneal metastasis

10.1093/jnci/djab001 · 2021 · External reference

Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases

10.1016/j.ejso.2021.05.046 · 2021 · External reference

Patterns and timing of recurrence following CRS and HIPEC in colorectal cancer peritoneal metastasis

10.1016/j.ejso.2022.07.019 · 2023 · External reference

The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy

10.1016/j.ejso.2021.08.027 · 2022 · External reference

Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

10.1038/s41416-021-01620-6 · 2022 · External reference

In patients undergoing CRS/HIPEC for colorectal adenocarcinoma with peritoneal metastases, presence of ascites on computed tomography imaging is not a prognostic marker for survival

10.1245/s10434-022-11718-7 · 2022 · External reference

Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma

10.1245/s10434-022-11805-9 · 2022 · External reference

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre

10.1111/ans.17761 · 2022 · External reference

Peritoneal metastases of colorectal origin treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy: the efficiency of mitomycin C

10.1245/s10434-022-12221-9 · 2022 · External reference

Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

10.1016/j.suronc.2022.101848 · 2022 · External reference

Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland colorectal peritoneal metastases registry

10.1038/s41416-022-02037-5 · 2023 · External reference

RAS mutation status should not be used to predict outcome from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases

10.1245/s10434-022-12704-9 · 2023 · External reference

10.21873/anticanres.16530

10.21873/anticanres.16530 · 2023 · External reference

Perioperative and oncological outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of rectal origin

10.1007/s11605-023-05833-3 · 2023 · External reference

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan

10.1097/js9.0000000000000809 · 2024 · External reference

Actual 5-Year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin

10.1245/s10434-023-14608-8 · 2024 · External reference

Extremely high peritoneal cancer index in colorectal peritoneal metastases demonstrates safety and overall survival benefit in selected patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

10.1002/wjs.12080 · 2024 · External reference

Recurrence and survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for synchronous and metachronous peritoneal metastases of colorectal origin

10.3390/cancers16030631 · 2024 · External reference

Hyperthermic intraperitoneal chemotherapy in colorectal cancer

10.1093/bjsopen/zrae017 · 2024 · External reference

A narrative review of what can HIPEC do

10.1016/j.ejso.2023.07.002 · 2023 · External reference

Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy

2003 · External reference

RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score

10.1245/s10434-019-07378-9 · 2019 · External reference

Clinical and molecular features in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from colorectal cancer

10.1007/s11605-021-05073-3 · 2021 · External reference

Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC

10.1002/jso.26439 · 2021 · External reference

Impact of primary tumor location and genomic alterations on survival following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for colorectal peritoneal metastases

10.1245/s10434-023-13463-x · 2023 · External reference

Prognostic impact of primary side and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases

10.1245/s10434-020-09161-7 · 2021 · External reference

Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin

10.1097/sla.0000000000002899 · 2018 · External reference

Circulating tumor DNA testing for minimal residual disease and its application in colorectal cancer

10.3390/cells14030161 · 2025 · External reference

The utility of ctDNA in colorectal cancer with peritoneal metastases

10.1111/ans.18078 · 2023 · External reference

Role of circulating tumor DNA among patients with colorectal peritoneal metastases

10.1007/s12029-023-00959-8 · 2024 · External reference

Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial

10.1016/s1470-2045(26)00085-9 · 2026 · External reference

Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials

10.1002/cam4.1126 · 2017 · External reference

Association of inflammatory biomarkers with survival among patients with stage III Colon cancer

10.1001/jamaoncol.2022.6911 · 2023 · External reference